Long-Term Adverse Health Outcomes in Survivors of Germ Cell Tumors Treated with High Dose Chemotherapy
M
Mohammad Abu Zaid, MD
Primary Investigator
Overview
The purpose of this study is to compare men who were treated for testicular cancer and received high dose cisplatin-based chemotherapy and peripheral blood stem cell transplant to those who received conventional doses of cisplatin-based chemotherapy for treatment of the same disease and men who have never been diagnosed with cancer.
Description
Participants will complete a health and medical history questionnaire, and provide consent for researchers to review their medical record.
Participants may also provide a blood sample and vital signs, as well as allow researchers to utilize any currently stored bio-specimen product that may have been stored after their stem cell transplant. These are optional and not required to participate in the study.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Germ Cell Tumors, Testicular Cancer
-
Age: Between 18 Years - 65 Years
-
Gender: Male
Men between 18 and 65 years of age whose treatment consisted of HDCT with stem cell transplant for testicular and extragonadal GCT.
Updated on
02 May 2024.
Study ID: 1712400404
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
